Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Japan: Hepatitis C drug fakes found in Nara drugstore chain

    Counterfeits of the hepatitis C drug Harvoni have been found at a drugstore chain in Nara Prefecture, the health ministry said Tuesday. Harvoni is sold by a Japanese unit of U.S. pharmaceutical firm Gilead Sciences Inc. The ingredients of the counterfeits are now under examination.

    18 January 2017 | The Japan Times
  • The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

    The U.S. government could cure most Americans suffering from hepatitis C infections if it simply bought drug maker Gilead Sciences on the stock market rather than purchasing its products in the drug market.

    17 January 2017 | Forbes
  • Access to highly effective hepatitis C treatment in Portugal: A Community Perspective

    This document presents a case study of community engagement for highly effective hepatitis C treatment, led by the Grupo de Ativistas em Tratamentos. It demonstrates the process of price and reimbursement negotiations in Portugal and lessons learned in advocacy for universal (or as close as possible) access to these and other life-saving drugs.

    19 December 2016 | EATG
  • Gilead’s Patent Loss to Merck Started With a Broken Friendship

    Jury may have been swayed by ‘story of betrayal,’ lawyers say. Gilead will use law, not emotion, to seek to overturn verdict.

    19 December 2016 | Bloomberg
  • Hepatitis C patients 'go abroad for drugs'

    Charities and liver specialists are warning that people with Hepatitis C are buying medications from India, to avoid long waits on the NHS. Radio 4's You & Yours has seen confidential documents, which suggest the cost to the NHS of some medications has dropped by nearly three-quarters, but experts say that NHS England still has not increased the number of patients it will treat.

    19 December 2016 | BBC Radio 4 (audio)
  • Merck wins $2.54 billion in hepatitis C drug trial against Gilead

    Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

    16 December 2016 | Reuters
  • Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months

    Hepatitis C medications approved in March this year have already topped the list of Australia's most expensive drugs, costing the taxpayer $1 billion. The latest figures have outlined 10 most prescribed and most expensive drugs on the Pharmaceutical Benefits Scheme (PBS) in the past year.

    05 December 2016 | ABC Online
  • New WHO report shows strategic purchasing of medicines can improve access in the European Region

    A new WHO report provides insight into how countries in the WHO European Region can improve access and reduce medicine prices through strategic and well-planned procurement processes. The report examines the effect of different public procurement practices on supply security and prices for pharmaceuticals. It also addresses collaboration within and across countries to improve availability of affordable medicines for patients in the Region.

    02 December 2016 | World Health Organization
  • DAA treatment restricted for Canadian hepatitis C patients

    Patients infected by hepatitis C virus (HCV) in Canada have limited access to direct-acting antiviral (DAA) agents, according to a new study. For example, 85% to 92% of the provinces and territories in Canada restrict access to these medications to persons with moderate fibrosis.

    29 November 2016 | Medical Economics
  • Where hepatitis C rates are seven times the US average — and a cure is kept out of reach

    With the opioid epidemic steamrolling through Appalachia, the new face of hepatitis C is increasingly young, white, and rural. In Kentucky, a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach.

    14 November 2016 | STAT
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.